DOCSLIB.ORG

Dry Eyes That Are Progressively Worse Throughout the Day, Which Causes Major Discomfort, Foreign Body Sensation and Photophobia

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

I. Case History: Patient demographics: 66 year old Asian female Chief complaint: Dry eyes that are progressively worse throughout the day, which causes major discomfort, foreign body sensation and photophobia. Ocular, medical history: Mild myope with presbyopia, spectacle Rx, no contact lens wear, Cataract extraction with posterior chamber intraocular lens implants both eyes. Patient referred to office for severe non-Sjogren’s keratoconjunctivitis sicca Current ocular medications: Lotemax steroid ophthalmic drops three times per day in both eyes, Systane artificial tears at least 5 times per day in both eyes. History of Nano Tears, Muro 128 hypertonic saline solution, N-acetylcysteine 5%, cyclosporine A and lifitegrast use. Other salient information: Patient has tattoo eyeliner on both upper and lower lid margins of both eyes II. Pertinent findings: Clinical: Reduced vision, BCVA 20/50 OD, 20/70 OS Conjunctival injection, grade 4+ (severe) interpalpebral superficial keratitis OS worse than OD, several small fine epithelial filaments on the corneal surface OD, 1 medium size epithelial filament and 1 large central epithelial filament with several small fine epithelial filaments OS, minimal meibomian gland expression with severe gland atrophy and tattoo eyeliner along inferior and superior lid margins OU. (will support with pictures) Other: Meibography: Severe grade 4 meibomian gland dropout of both lower lids. (will support with pictures) III. Differential diagnosis: Primary/leading: Keratoconjunctivitis Sicca with subsequent severe, non-resolving filamentary keratitis Others: Non-autoimmune forms of aqueous deficient dry eye (Keratoconjunctivitis sicca non-Sjogren’s syndrome), Autoimmune related aqueous deficient dry eye (Keratoconjunctivitis sicca, Sjogren’s syndrome), Bacterial keratitis, Viral keratitis, Staph marginal keratitis, Exposure keratopathy, Superior limbic keratoconjunctivitis, Corneal edema, Prolonged occlusion, Cataract surgery, Penetrating keratoplasty, Photorefractive keratectomy, Bell’s Palsy, Neurotrophic keratitis IV. Diagnosis and discussion: Filamentary keratitis is a severe ocular surface condition that is characterized by “fine strands of degenerated epithelial cells with mucous attached to the cornea (1).” Epithelial damage of the basement membrane causes elevated areas of the cornea allowing for muscin to build up around these elevated areas. This build up creates the filaments, which adhere to the corneal epithelium. The mechanical action of the lids rubbing over the filaments during a blink is what causes the symptoms of pain and subsequent tearing and inflammation. The clinical presentation is classic for mucous filaments on the corneal surface, interpalpebral corneal staining, mucous debris in the inferior cul-de-sac and diffuse conjunctival injection. V. Treatment, management: Initiate treatment with N-acetylcysteine 10% QID OU, Retaine MGD artificial tears QID OU and Systane lubricating gel QHS OU. Debridement of the filaments with forceps and amniotic membrane transplantation performed OS only. Four days later at the patient’s next follow up, she reports non-compliance with the N-acetylcysteine 10% and states first instillation was that morning. There is complete resolution of filaments and improvement in interpalpebral punctate keratitis OS. Her right eye clinical findings are all unchanged since the previous visit. The amniotic membrane is removed from OS at this office visit. The patient then returns in 14 days. At this visit, the patient is less symptomatic with no filaments OD and trace filaments OS. Interpalpebral staining is still significant OU. At this visit, the amniotic membrane is placed in the right eye due to the significant staining still present OD. The filaments are debrided on the left eye with a bandage contact lens placed afterwards. The patient is scheduled to return in one week from this visit for amniotic membrane and bandage contact lens removal. She is to continue N-acetylcysteine 10% QID OU, Retaine MGD artificial tears QID OU and Systane lubricating gel QHS OU. On the follow up visit for membrane removal OD, there is improvement in staining and new bandage contact lenses are placed OU. The patient reports significant improvement in her symptoms. The patient discussed in this case has severe keratoconjunctivitis sicca, which is most likely due to her nearly total meibomian gland atrophy. Treatment to help her underlying keratoconjunctivitis sicca is aimed at improving her meibomian gland dysfunction (MGD), therefore, Retain MGD artificial tears are prescribed for this patient. Another interesting aspect of this patient’s history is the tattoo eyeliner on the inferior and superior lid margins of both of her eyes. The procedure of micropigmentation of the eyelid margin has been found to be associated with total meibomian gland dropout. It was also found that traditional meibomian gland therapy was not useful on these patients that presented with complete gland atrophy (3). The literature on this subject is variable. As with most ocular diseases, treatment is dependent on the patient and can be quite different when comparing cases. With that said, generally, the most consistent strategies for managing filamentary keratitis include the following: debridement of large filaments, generous lubrication of the ocular surface, and treatment of the underlying cause (2). Debridement is typically performed solely on large filaments and is done with forceps and involves subsequent antibiotic coverage. Lubrication can be done with any type of artificial tear in addition to a gel or ointment at night. Lastly, depending on the patient’s root cause of the filamentary keratitis, the treatment changes in order to control this factor. Additional treatments for severe dry eye syndrome that will be further explored are autologous serum tears and scleral lenses. (treatment and management will be further supported by current research and literature) Bibliography: (1) Albietz J, Sanfilippo P, Troutbeck R, Lenton L. Management of Filamentary Keratitis Associated with Aqueous- Deficient Dry Eye. Optometry and Vision Science. 2003; 80(6): 420-430. (2) Filamentary Keratitis. Review of Optometry Cornea. June 2015. 31A-32A (3) Kojima T, Dogru M, Matsumoto Y, et al. Tear film and ocular surface abnormalities after eyelid tattooing. Ophthal Plast Reconstr Surg. 2005 Jan; 21(1): 69-71. (4) Harminder S Dua. Amniotic membrane transplantation. British Journal of Ophthalmology. 2017; 83(6). (5) Kabat A, Sowka J. Fighting Filamentary Keratitis. Review of Optometry. Feb 2015. (6) Cremers S. Best Way to Treat Filamentary Keratitis. Fellow of the American Board of Ophthalmology. Sep 2015. (7) Zaldman GW, Geeraets R, Paylor RR, Ferry AP. The histopathology of filamentary keratitis. Arch Ophthalmol. 1985 Aug: 103(8) 1178-81. (8) Kang MH, Kim MK, Lee HJ, Wee WR, Lee JH. Interleukin-17 in various ocular surface inflammatory diseases. J Korean Med Sci. 2011 Jul; 26(7) 938-44. VI. Conclusion: Filamentary keratitis is a serious clinical finding that is indicative of an extremely compromised ocular surface. Although there are numerous treatment options that can be considered for these patients, the case presented in this report shows that N-acetylcysteine 10% and amniotic membrane transplantation are two treatments that have relatively quick and positive outcomes. The combination of N-acetylcysteine 10% and amniotic membrane transplantation that was used in this case showed to have a rapid response and resolution of the filamentary keratitis. When treating a complex disease such as filamentary keratitis, it is important to explore all options for the patient and tailor the treatment options based on the underlying etiology of the disease. .
Recommended publications
  • In Vivo Confocal Microscopy of Toxic Keratopathy

    In Vivo Confocal Microscopy of Toxic Keratopathy

    Eye (2017) 31, 140–147 OPEN Official journal of The Royal College of Ophthalmologists www.nature.com/eye CLINICAL STUDY In vivo confocal Y Chen, Q Le, J Hong, L Gong and J Xu microscopy of toxic keratopathy Abstract Purpose To explore the morphological although a wide variety of chemicals and characteristics of toxic keratopathy (TK), systemic medications can also cause TK.1 Cases which clinically presented as superficial of drug-induced TK have been prevalent in punctate keratopathy (SPK), with the ophthalmic clinics for two reasons. On the one application of in vivo laser-scanning confocal hand, most of the topically applied drugs, either microscopy (LSCM), and evaluate its potential prescribed or sold over-the-counter, are capable in the early diagnosis of TK. of causing corneal damage at sufficient Patients and methods This was a cross- concentrations.2 Patients who have glaucoma, sectional study involving 16 patients with viral keratitis, keratoconjunctivitis sicca or other TK and 16 patients with dry eye (DE), ocular surface conditions, generally need demonstrating SPK under slit-lamp multidrug remedies, and these pre-existing observation, and 10 normal eyes were conditions may especially predispose them to enrolled in the study. All participants drug toxicity. The preservative in the eye drops, underwent history interviews, fluorescein mainly benzalkonium chloride (BAC), is another staining, tear film break-up time (BUT) tests, important cause for epithelial lesions. On the Schirmer tests, and in vivo LSCM. other hand, the use of eye drops for a week or Results The area grading of corneal more may cause TK, which can often be confused fluorescein punctate staining was higher in with the worsening of the patient’s initial disease the TK group than the DE group.
  • Differentiate Red Eye Disorders

    Differentiate Red Eye Disorders

    Introduction DIFFERENTIATE RED EYE DISORDERS • Needs immediate treatment • Needs treatment within a few days • Does not require treatment Introduction SUBJECTIVE EYE COMPLAINTS • Decreased vision • Pain • Redness Characterize the complaint through history and exam. Introduction TYPES OF RED EYE DISORDERS • Mechanical trauma • Chemical trauma • Inflammation/infection Introduction ETIOLOGIES OF RED EYE 1. Chemical injury 2. Angle-closure glaucoma 3. Ocular foreign body 4. Corneal abrasion 5. Uveitis 6. Conjunctivitis 7. Ocular surface disease 8. Subconjunctival hemorrhage Evaluation RED EYE: POSSIBLE CAUSES • Trauma • Chemicals • Infection • Allergy • Systemic conditions Evaluation RED EYE: CAUSE AND EFFECT Symptom Cause Itching Allergy Burning Lid disorders, dry eye Foreign body sensation Foreign body, corneal abrasion Localized lid tenderness Hordeolum, chalazion Evaluation RED EYE: CAUSE AND EFFECT (Continued) Symptom Cause Deep, intense pain Corneal abrasions, scleritis, iritis, acute glaucoma, sinusitis, etc. Photophobia Corneal abrasions, iritis, acute glaucoma Halo vision Corneal edema (acute glaucoma, uveitis) Evaluation Equipment needed to evaluate red eye Evaluation Refer red eye with vision loss to ophthalmologist for evaluation Evaluation RED EYE DISORDERS: AN ANATOMIC APPROACH • Face • Adnexa – Orbital area – Lids – Ocular movements • Globe – Conjunctiva, sclera – Anterior chamber (using slit lamp if possible) – Intraocular pressure Disorders of the Ocular Adnexa Disorders of the Ocular Adnexa Hordeolum Disorders of the Ocular
  • Refractive Surgery Faqs. Refractive Surgery the OD's Role in Refractive

    Refractive Surgery Faqs. Refractive Surgery the OD's Role in Refractive

    9/18/2013 Refractive Surgery Refractive Surgery FAQs. Help your doctor with refractive surgery patient education Corneal Intraocular Bill Tullo, OD, FAAO, LASIK Phakic IOL Verisys Diplomate Surface Ablation Vice-President of Visian PRK Clinical Services LASEK CLE – Clear Lens Extraction TLC Laser Eye Centers Epi-LASIK Cataract Surgery AK - Femto Toric IOL Multifocal IOL ICRS - Intacs Accommodative IOL Femtosecond Assisted Inlays Kamra The OD’s role in Refractive Surgery Refractive Error Determine the patient’s interest Myopia Make the patient aware of your ability to co-manage surgery Astigmatism Discuss advancements in the field Hyperopia Outline expectations Presbyopia/monovision Presbyopia Enhancements Risks Make a recommendation Manage post-op care and expectations Myopia Myopic Astigmatism FDA Approval Common Use FDA Approval Common Use LASIK: 1D – 14D LASIK: 1D – 8D LASIK: -0.25D – -6D LASIK: -0.25D – -3.50D PRK: 1D – 13D PRK: 1D – 6D PRK: -0.25D – -6D PRK: -0.25D – -3.50D Intacs: 1D- 3D Intacs: 1D- 3D Intacs NONE Intacs: NONE P-IOL: 3D- 20D P-IOL: 8D- 20D P-IOL: NONE P-IOL: NONE CLE/CAT: any CLE/CAT: any CLE/CAT: -0.75D - -3D CLE/CAT: -0.75D - -3D 1 9/18/2013 Hyperopia Hyperopic Astigmatism FDA Approval Common Use FDA Approval Common Use LASIK: 0.25D – 6D LASIK: 0.25D – 4D LASIK: 0.25D – 6D LASIK: 0.25D – 4D PRK: 0.25D – 6D PRK: 0.25D – 4D PRK: 0.25D – 6D PRK: 0.25D – 4D Intacs: NONE Intacs: NONE Intacs: NONE Intacs: NONE P-IOL: NONE P-IOL: NONE P-IOL: NONE P-IOL:
  • Onchocerciasis

    Onchocerciasis

    11 ONCHOCERCIASIS ADRIAN HOPKINS AND BOAKYE A. BOATIN 11.1 INTRODUCTION the infection is actually much reduced and elimination of transmission in some areas has been achieved. Differences Onchocerciasis (or river blindness) is a parasitic disease in the vectors in different regions of Africa, and differences in cause by the filarial worm, Onchocerca volvulus. Man is the the parasite between its savannah and forest forms led to only known animal reservoir. The vector is a small black fly different presentations of the disease in different areas. of the Simulium species. The black fly breeds in well- It is probable that the disease in the Americas was brought oxygenated water and is therefore mostly associated with across from Africa by infected people during the slave trade rivers where there is fast-flowing water, broken up by catar- and found different Simulium flies, but ones still able to acts or vegetation. All populations are exposed if they live transmit the disease (3). Around 500,000 people were at risk near the breeding sites and the clinical signs of the disease in the Americas in 13 different foci, although the disease has are related to the amount of exposure and the length of time recently been eliminated from some of these foci, and there is the population is exposed. In areas of high prevalence first an ambitious target of eliminating the transmission of the signs are in the skin, with chronic itching leading to infection disease in the Americas by 2012. and chronic skin changes. Blindness begins slowly with Host factors may also play a major role in the severe skin increasingly impaired vision often leading to total loss of form of the disease called Sowda, which is found mostly in vision in young adults, in their early thirties, when they northern Sudan and in Yemen.
  • Posterior Cornea and Thickness Changes After Scleral Lens Wear in Keratoconus Patients

    Posterior Cornea and Thickness Changes After Scleral Lens Wear in Keratoconus Patients

    Contact Lens and Anterior Eye xxx (xxxx) xxx–xxx Contents lists available at ScienceDirect Contact Lens and Anterior Eye journal homepage: www.elsevier.com/locate/clae Posterior cornea and thickness changes after scleral lens wear in keratoconus patients Maria Serramitoa, Carlos Carpena-Torresa, Jesús Carballoa, David Piñerob,c, Michael Lipsond, ⁎ Gonzalo Carracedoa,e, a Department of Optics II (Optometry and Vision), Faculty of Optics and Optometry, Universidad Complutense de Madrid, Madrid, Spain b Group of Optics and Visual Perception, Department of Optics, Pharmacology and Anatomy, University of Alicante, Spain c Department of Ophthalmology (OFTALMAR), Vithas Medimar International Hospital, Alicante, Spain d Department of Ophthalmology and Visual Science, University of Michigan, Northville, MI, USA e Ocupharm Group Research, Department of Biochemistry and Molecular Biology IV, Faculty of Optics and Optometry, Universidad Complutense de Madrid, Madrid, Spain ARTICLE INFO ABSTRACT Keywords: Purpose: To evaluate the changes in the corneal thickness, anterior chamber depth and posterior corneal cur- Scleral lenses vature and aberrations after scleral lens wear in keratoconus patients with and without intrastromal corneal ring Keratoconus segments (ICRS). Corneal curvature Methods: Twenty-six keratoconus subjects (36.95 ± 8.95 years) were evaluated after 8 h of scleral lens wear. Corneal aberrations The subjects were divided into two groups: those with ICRS (ICRS group) and without ICRS (KC group). The Anterior chamber study variables evaluated before and immediately after scleral lens wear included corneal thickness evaluated in Corneal thickness different quadrants, posterior corneal curvature at 2, 4, 6 and 8 mm of corneal diameter, posterior corneal aberrations for 4, 6 and 8 mm of pupil size and anterior chamber depth.
  • Diagnosis and Treatment of Neurotrophic Keratopathy

    Diagnosis and Treatment of Neurotrophic Keratopathy

    An Evidence-based Approach to the Diagnosis and Treatment of Neurotrophic Keratopathy ACTIVITY DIRECTOR A CME MONOGRAPH Esen K. Akpek, MD This monograph was published by Johns Hopkins School of Medicine in partnership Wilmer Eye Institute with Catalyst Medical Education, LLC. It is Johns Hopkins School of Medicine not affiliated with JAMA medical research Baltimore, Maryland publishing. Visit catalystmeded.com/NK for online testing to earn your CME credit. FACULTY Natalie Afshari, MD Mina Massaro-Giordano, MD Shiley Eye Institute University of Pennsylvania School of Medicine University of California, San Diego Philadelphia, Pennsylvania La Jolla, California Nakul Shekhawat, MD, MPH Sumayya Ahmad, MD Wilmer Eye Institute Mount Sinai School of Medicine Johns Hopkins School of Medicine New York, New York Baltimore, Maryland Pedram Hamrah, MD, FRCS, FARVO Christopher E. Starr, MD Tufts University School of Medicine Weill Cornell Medical College Boston, Massachusetts New York, New York ACTIVITY DIRECTOR FACULTY Esen K. Akpek, MD Natalie Afshari, MD Mina Massaro-Giordano, MD Professor of Ophthalmology Professor of Ophthalmology Professor of Clinical Ophthalmology Director, Ocular Surface Diseases Chief of Cornea and Refractive Surgery University of Pennsylvania School and Dry Eye Clinic Vice Chair of Education of Medicine Wilmer Eye Institute Fellowship Program Director of Cornea Philadelphia, Pennsylvania Johns Hopkins School of Medicine and Refractive Surgery Baltimore, Maryland Shiley Eye Institute Nakul Shekhawat, MD, MPH University of California,
  • Medical Policy Gas Permeable Scleral Contact Lens

    Medical Policy Gas Permeable Scleral Contact Lens

    Medical Policy Gas Permeable Scleral Contact Lens Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy: Medicare Description References Authorization Information Policy History Policy Number: 371 BCBSA Reference Number: 9.03.25 Related Policies Corneal Topography/Computer-Assisted Corneal Topography/Photokeratoscopy, #301 Implantation of Intrastromal Corneal Ring Segments, #235 Policy Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members Rigid gas permeable scleral lens may be considered MEDICALLY NECESSARY for patients who have not responded to topical medications or standard spectacle or contact lens fitting, for the following conditions: Corneal ectatic disorders (e.g., keratoconus, keratoglubus, pellucid marginal degeneration, Terrien’s marginal degeneration, Fuchs’ superficial marginal keratitis, post-surgical ectasia); Corneal scarring and/or vascularization; Irregular corneal astigmatism (e.g., after keratoplasty or other corneal surgery); Ocular surface disease (e.g., severe dry eye, persistent epithelial defects, neurotrophic keratopathy, exposure keratopathy, graft vs. host disease, sequelae of Stevens Johnson syndrome, mucus membrane pemphigoid, post-ocular surface tumor excision, post-glaucoma filtering surgery) with pain and/or decreased visual acuity. Prior Authorization Information Commercial Members: Managed Care (HMO and POS) Prior authorization is NOT required. Commercial Members: PPO, and Indemnity
  • Immune Defense at the Ocular Surface

    Immune Defense at the Ocular Surface

    Eye (2003) 17, 949–956 & 2003 Nature Publishing Group All rights reserved 0950-222X/03 $25.00 www.nature.com/eye Immune defense at EK Akpek and JD Gottsch CAMBRIDGE OPHTHALMOLOGICAL SYMPOSIUM the ocular surface Abstract vertebrates. Improved visual acuity would have increased the fitness of these animals and would The ocular surface is constantly exposed to a have outweighed the disadvantage of having wide array of microorganisms. The ability of local immune cells and blood vessels at a the outer ocular system to recognize pathogens distance where a time delay in addressing a as foreign and eliminate them is critical to central corneal infection could lead to blindness. retain corneal transparency, hence The first vertebrates were jawless fish that preservation of sight. Therefore, a were believed to have evolved some 470 million combination of mechanical, anatomical, and years ago.1 These creatures had frontal eyes and immunological defense mechanisms has inhabited the shorelines of ancient oceans. With evolved to protect the outer eye. These host better vision, these creatures were likely more defense mechanisms are classified as either a active and predatory. This advantage along with native, nonspecific defense or a specifically the later development of jaws enabled bony fish acquired immunological defense requiring to flourish and establish other habitats. One previous exposure to an antigen and the such habitat was shallow waters where lunged development of specific immunity. Sight- fish made the transition to land several hundred threatening immunopathology with thousand years later.2 To become established in autologous cell damage also can take place this terrestrial environment, the new vertebrates after these reactions.
  • Treatment of Interface Keratitis with Oral Corticosteroids

    Treatment of Interface Keratitis with Oral Corticosteroids

    Treatment of interface keratitis with oral corticosteroids Scott M. MacRae, MD, Larry F. Rich, MD, Damien C. Macaluso, MD ABSTRACT Purpose: To describe the results of treating interface keratitis using a combination of intensive topical and oral corticosteroids. Setting: Casey Eye Institute, Portland, Oregon, USA. Methods: Thirteen eyes treated for grade 2 to 3 interface keratitis using an oral cortico- steroid (prednisone 60 to 80 mg) as well as an hourly topical corticosteroid were retrospectively reviewed. The best corrected visual acuity (BCVA) was used as an objective guide of whether to treat with intense topical and oral corticosteroids, flap irrigation, or both. Predisposing factors such as intraoperative epithelial defects or a history of severe allergies or atopy were also looked for. Results: All 13 eyes responded favorably to the combination of intensive topical and oral corticosteroids and had a BCVA of 20/20 after the keratitis resolved. In 6 eyes (46%), the patients had a history of severe seasonal allergies. One day postoperatively, 3 eyes (23%) had an epithelial defect and 2 eyes (15%), lint particles or debris embedded in the interface. With oral corticosteroid use, 3 patients (23%) noted mild stomach irritation and 2 (15%) noted nervousness. All 5 side effects resolved without sequelae. No patient developed a serious side effect. Conclusion: A short, intense course of an oral corticosteroid was an effective treatment in patients with grade 2 or higher interface keratitis when combined with a topical corti- costeroid administered hourly. The BCVA is a helpful objective measure of the severity of interface keratitis and can be used to guide the clinician in the therapeutic strategy.
  • Frequency and Risk Factors of Symptomatic Dry Eye Disease at Tertiary Care Eye Hospital, Karachi

    Frequency and Risk Factors of Symptomatic Dry Eye Disease at Tertiary Care Eye Hospital, Karachi

    Biostatistics and Biometrics Open Access Journal ISSN: 2573-2633 Research Article Biostat Biometrics Open Acc J Faisal’s Issue - January 2018 Copyright © All rights are reserved by Muhammad Faisal Fahim DOI: 10.19080/BBOAJ.2018.04.555639 Frequency and Risk Factors of Symptomatic Dry Eye Disease at Tertiary Care Eye Hospital, Karachi Shaheerah Gul1, Adil Salim Jafri1, Muhammad Faisal Fahim2* 1Department of Ophthalmology, Al-Ibrahim Eye Hospital, Pakistan 2Department of Research & Development, Al-Ibrahim Eye Hospital, Pakistan Submission: November 27, 2017; Published: January 19, 2018 *Corresponding author: Muhammad Faisal Fahim, M.Sc (Statistics), Statistician, Research & Development Department, Al-Ibrahim Eye Hospital, Isra postgraduate Institute of Ophthalmology, Karachi, Pakistan, Tel: ; Email: Abstract Objective: To determine frequency and risk factors of symptomatic dry eye disease at tertiary care eye hospital, Karachi. Material & Methods: This was a descriptive cross sectional study carried out at Al-Ibrahim Eye Hospital, Isra postgraduate Institute of Oph- thalmology, Karachi from March to October 2016. Non-Probability purposive sampling technique was used for data collection. Inclusion criteria give consent. Symptoms of dry eye were assessed using Tear breakup test (TBUT) test. SPSS version 20.0 was used to analyze data. were patients aged ≥ 21 years and on the basis of dry eye symptoms. Exclusion criteria were other systemic eye disease and those who did not Results: A total of 100 patients 65 female and 35 male were diagnosed with dry eye syndrome. The age group of 21-30 years having the high- est frequency of 34 patients, whereas after the 50 years of age the frequency of patients decreases to 21.
  • Eye Care in the Intensive Care Unit (ICU)

    Eye Care in the Intensive Care Unit (ICU)

    Ophthalmic Services Guidance Eye Care in the Intensive Care Unit (ICU) June 2017 18 Stephenson Way, London, NW1 2HD T. 020 7935 0702 [email protected] rcophth.ac.uk @RCOphth © The Royal College of Ophthalmologists 2017 All rights reserved For permission to reproduce any of the content contained herein please contact [email protected] Contents Section page 1 Summary 3 2 Introduction 3 Protecting the eye of the vulnerable patient 4 3 Identifying disease of the eye 6 Exposure keratopathy and corneal abrasion 6 Chemosis 8 Microbial infections 8 4 Rare eye conditions in ICU 10 Red eye in a septic patient: possible endogenous endophthalmitis 10 Other problems 11 5 Delivering treatment to the eye when it is prescribed 11 Red eye in ICU patient 12 6. Systemic fungal infection and the eye for intensivists 14 7. Tips for ophthalmologists seeing patients in ICU 14 8. Authors 16 9. References 17 Date of review: July 2020 2017/PROF/350 2 1 Summary This document aims to provide advice and information for clinical staff who are involved in eye care in the ICU. It is primarily intended to help non-ophthalmic ICU staff to: 1. protect the eye in vulnerable patients, thus preventing ICU-related eye problems 2. identify disease affecting the eye in ITU patients, and specifically those which might need ophthalmic referral 3. deliver treatment to the eye when it is prescribed It concentrates primarily on the common problems of the eye surface but also touches on other less common conditions. As such, it should also be helpful to those ophthalmologists asked for advice about ICU patients.
  • Microbial Keratitis After Corneal Collagen Crosslinking

    Microbial Keratitis After Corneal Collagen Crosslinking

    CASE REPORT Microbial keratitis after corneal collagen crosslinking Juan J. Pe´rez-Santonja, MD, Alberto Artola, MD, Jaime Javaloy, MD, Jorge L. Alio´, MD, PhD, Jose´L. Abad, PhD Several infiltrates appeared in the upper midperipheral cornea of a 29-year-old woman who had had uneventful corneal collagen crosslinking (CXL) with riboflavin and ultraviolet-A light (UVA) for the treatment of keratoconus in the right eye. Staphylococcus epidermidis keratitis was con- firmed by microbiological studies, which guided treatment with topical fortified antibiotic agents. Before CXL, the best spectacle-corrected visual acuity (BSCVA) in the right eye was 20/25, the manifest refraction was À0.25 À0.25 Â 125, and the anterior segment was normal under biomi- croscopy. Five months after the procedure, the BSCVA was 20/22, the manifest refraction was C1.00 À2.50 Â 40, and slitlamp examination revealed a mild residual haze in the upper midper- ipheral cornea. Collagen crosslinking with riboflavin–UVA is a minimally invasive method but tra- ditionally requires epithelial removal, which could be a predisposing factor to bacterial keratitis. J Cataract Refract Surg 2009; 35:1138–1140 Q 2009 ASCRS and ESCRS Keratoconus is a noninflammatory ectasia of the cor- light (UVA) has been developed.3 This technique in- nea that is usually bilateral. The condition typically creases the corneal rigidity of treated corneas, and pre- starts at puberty, progressing in approximately 20% liminary clinical studies have shown improvement of cases to the extent that keratoplasty is necessary.1 and stabilization of keratectasia with few, if any, com- Hard contact lenses and corneal grafting have been plications in patients with keratoconus.4,5 the major treatment modalities for keratoconus, We report a case of microbial keratitis that devel- although some patients can now benefit from intracor- oped after CXL with riboflavin and UVA for the treat- neal ring segment implantation.1,2 None of these tech- ment of keratoconus.